Project description:The 19th Annual Meeting of the Association for Cancer Immunotherapy (CIMT), Europe's cancer immunotherapy meeting, was the first in-person event organized by CIMT since the beginning of the COVID-19 pandemic. As a hybrid event from May 10-12, the meeting attracted 920 academic and clinical professionals from over 40 countries, who met to discuss the latest advances in cancer immunology and immunotherapy research. This report summarizes the highlights of CIMT2022.

| S-EPMC9746370 | biostudies-literature

CIMT 2021: report on the 18th Annual Meeting of the Association for Cancer Immunotherapy.

Project description:After one year of absence, the 18th Annual Meeting of the Association for Cancer Immunotherapy (CIMT), Europe's cancer immunotherapy meeting, took place virtually from 10 to 12 May 2021. Over 850 academic and clinical professionals from 30 countries met to discuss the recent advancements in cancer immunotherapy and the current progress in COVID19-related research. This meeting report summarizes the highlights of CIMT2021.

| S-EPMC8993083 | biostudies-literature

CIMT 2023: report on the 20th Annual Meeting of the Association for Cancer Immunotherapy.

Project description:The Association for Cancer Immunotherapy (CIMT) celebrated the 20th anniversary of the CIMT Annual Meeting. CIMT2023 was held 3-5 May 2023 in Mainz, Germany. 1051 academic and clinical professionals from over 30 countries attended the meeting and discussed the latest advances in cancer immunology and immunotherapy research. This report summarizes the highlights of CIMT2023.

| S-EPMC10590812 | biostudies-literature

CIMT 2018: Pushing frontiers in cancer immunotherapy - Report on the 16th Annual Meeting of the Association for Cancer Immunotherapy.

Project description:The 16th Annual Meeting of the Association for Cancer Immunotherapy (CIMT), Europe's largest meeting series of its kind, took place in Mainz, Germany from 15-17 May, 2018. Cutting-edge advancements in cancer immunotherapy were discussed among more than 700 scientists under the motto "Pushing Frontiers in Cancer Immunotherapy". This meeting report is a summary of some of the CIMT 2018 highlights.

| S-EPMC6343606 | biostudies-literature

CIMT 2016: Mechanisms of efficacy in cancer immunotherapy - Report on the 14th Annual Meeting of the Association for Cancer Immunotherapy May 10-12 2016, Mainz, Germany.

Project description: Not available

| S-EPMC5137546 | biostudies-literature

2015 ASCB Annual Meeting abstracts.

Project description: Not available

| S-EPMC4678009 | biostudies-literature

Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge”, Napoli, December 5th 2015

Project description:Harnessing the immune system and preventing immune escape, the immunotherapy of cancer provides great potential for clinical application, in broad patient populations, achieving both conventional and unconventional clinical responses. After the substantial advances in melanoma, the focus of cancer immunotherapy has expanded to include many other cancers. Targeting immune checkpoints and further mechanisms used by tumors to avoid anticancer immunity, different approaches are under evaluation, including combination therapies. The first Immunotherapy Bridge meeting focused on various cancer types including melanoma, non-small cell lung cancer, renal cell, breast and ovarian carcinoma, and discussed mechanisms of action of single agents and combination strategies, and the prediction of clinical responses.

| S-EPMC5067891 | biostudies-literature

American Society of Hematology 2015 Annual Meeting.

Project description:The annual meeting of the American Society of Hematology drew 25,000 attendees for the presentation of 5,633 abstracts. We review key sessions focusing on newer agents and their efficacy in high-risk leukemia and multiple myeloma populations.

| S-EPMC4745640 | biostudies-literature

American College of Rheumatology 2015 Annual Meeting.

Project description:Key sessions at the meeting covered the effects and relationships of early remission, weight, corticosteroids, and anti-tumor necrosis factor agents in rheumatic diseases.

| S-EPMC4699488 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data